Skip to site menu Skip to page content

Maxims for Early Phase Trials

By SGS

The aim of any study of a potential new drug product is to deliver a safe and effective treatment. Pharmaceutical companies need to achieve these goals in a way that can maximize safety and efficiency, while minimizing costs and negative impacts.

Early phase clinical trials are a critical part of any drug development program. They constitute the first stage, providing vital information on the tolerability, pharmacokinetics, mechanism of action, and safety of a drug. Without this data, drug development cannot proceed as it will be required as the study develops and moves to later phases.

In this white paper, we look at early phase clinical trials and consider the ways in which operators can optimize the study process.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content